NASDAQ:GMAB
Genmab ADR (GMAB)
Financials 
Technical Analysis 
Jun 8, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Genmab ADR (GMAB-Q) has recently garnered attention from analysts, fluctuating between strong potential and a challenged investment outlook. Stockchase Research highlighted its significant increase in revenues driven by proprietary cancer treatment sales, with a reported 19% growth. However, a previous position has resulted in a loss after triggering a stop loss at $24. Despite this, analysts advocate for the stock's potential, with estimates suggesting price targets around $36.75 to $37.42. The company benefits from substantial cash reserves, a solid return on equity of approximately 28%, and a favorable position strengthened by its royalty agreement with J&J. While the prospect appears optimistic, there is a recommendation to remain disciplined, potentially adjusting positions according to market performance.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentFollowing recently released earnings, we reiterate GMAB as a TOP PICK. The Danish based pharmaceutical company reported a 19% increase in revenues, thanks to a 54% increase in the sales of proprietary antibody treatments for cancer. Cash reserves grew while shares were aggressively bought back. It trades at 18x earnings, 3x book and supports a 17% ROE. We continue to recommend a stop at $24, looking to achieve $37 — upside potential of 32%. Yield 0%
(Analysts’ price target is $36.75)Premium contentGMAB is a biotech company based in the Netherlands producing human antibody treatments for cancer. It collects a royalty agreement with J&J that pays $14.3 billion, of which over half originates from the US and the balance from Europe. This is allowing for cash reserves to grow aggressively, while debt is retired. Annual EPS growth exceeds 28% over the past five years and analysts see growth over 20% over the next five. It trades at 16x earnings, 3.2x book and supports a 28% ROE. We recommend setting a stop-loss at $24, looking to achieve $37 -- upside potential of 23%. Yield 0%
(Analysts’ price target is $37.42)- «
- ‹
- 1
- ›
- »
Genmab ADR (GMAB) Frequently Asked Questions
What is Genmab ADR stock symbol?
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
Is Genmab ADR a buy or a sell?
In the last year, 3 stock analysts published opinions about GMAB (previously GMAB-Q on Stockchase). 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Is Genmab ADR a good investment or a top pick?
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-02-12. Read the latest stock experts ratings for Genmab ADR.
Why is Genmab ADR stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Genmab ADR worth watching?
In the last year, there was no coverage of Genmab ADR published on Stockchase.
What is Genmab ADR stock price?
On 2026-06-09, Genmab ADR (GMAB) stock closed at a price of $25.13.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.